Silence Therapeutics plc (NASDAQ:SLN) Shares Bought by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC raised its position in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 71.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 497,870 shares of the company's stock after acquiring an additional 208,029 shares during the period. Parkman Healthcare Partners LLC owned approximately 1.66% of Silence Therapeutics worth $9,051,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Values First Advisors Inc. purchased a new stake in Silence Therapeutics in the 3rd quarter worth about $56,000. Quarry LP purchased a new stake in shares of Silence Therapeutics in the second quarter worth approximately $114,000. Verition Fund Management LLC purchased a new stake in Silence Therapeutics in the third quarter worth $207,000. Custom Index Systems LLC purchased a new stake in Silence Therapeutics in the second quarter worth $282,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Silence Therapeutics during the third quarter worth approximately $318,000. Hedge funds and other institutional investors own 98.73% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SLN shares. Morgan Stanley reissued an "overweight" rating and set a $49.00 price objective on shares of Silence Therapeutics in a report on Tuesday, October 8th. William Blair reiterated an "outperform" rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. BMO Capital Markets reiterated an "outperform" rating on shares of Silence Therapeutics in a research note on Monday. Chardan Capital reiterated a "buy" rating and issued a $55.00 target price on shares of Silence Therapeutics in a research note on Thursday, November 14th. Finally, Jefferies Financial Group initiated coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $40.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $57.20.

Silence Therapeutics Trading Up 8.2 %

SLN traded up $0.63 on Wednesday, hitting $8.30. 640,047 shares of the company's stock were exchanged, compared to its average volume of 257,213. Silence Therapeutics plc has a fifty-two week low of $5.81 and a fifty-two week high of $27.72. The firm has a 50-day moving average price of $15.42 and a 200-day moving average price of $17.92. The stock has a market cap of $248.42 million, a price-to-earnings ratio of -4.99 and a beta of 1.05.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.